April 6, 2025
Rare Earth Investing Opportunity as China Strikes Back
This past Friday, Beijing, in response to the new U.S. tariffs, announced controls on exports of medium and heavy rare-earths.
I view these recent trade developments as a catalyst that further strengthens my favorite mining stocks investment theses.
The most recent Chinese export restrictions Friday include heavy rare-earth elements samarium, gadolinium, terbium, dysprosium, lutetium, scandium and yttrium to the U.S. This is just the most recent of many such export restrictions over recent years, even recent months.
Heavy rare earth mining company USA Rare Earth ticker USAR stock was up +16% Friday, despite the huge overall stock market sell-off. The relative strength is significant to me as very few stocks were positive Friday. The only major asset higher was U.S. Treasury bonds as investors sought safety.
> While the public and Wallstreet are hyper-focused on the tariffs, capital markets and economic consequences I see the element export controls as providing actionable opportunity catalysts. I see further catalysts likely also as we now have a clear trend with how China is reacting to trade tensions with export controls.
These recent tariff retaliatory actions from China are important because China processes approximately 90% of the world's rare earth elements and supplies 78% of U.S. demand.
In December 2024, China banned exports of gallium, germanium, and antimony to the U.S., citing their dual-use applications in semiconductors and defense technologies.
In February 2025, licensing requirements were put on tungsten, tellurium, bismuth, indium, and molybdenum. These metals are critical for electronics. To me this strengthens, even further, the investment thesis in U.S. rare earths and critical mining operations.
In addition, just weeks ago President Donald Trump on March 20,2025 made an executive order titled “Immediate Measures to Increase America’s Mineral Production.”
This directive aims to boost domestic production of critical minerals and reduce reliance on foreign imports. It is using the Defense Production Act (DPA).
The DPA is invoked to accelerate domestic mineral production by prioritizing mining projects critical to national security and industrial needs.
Federal agencies, including the Department of Defense (DoD), Department of Energy (DOE), and Department of the Interior (DOI), are directed to identify and expedite priority mineral production projects.
The order broadens the definition of "critical minerals" to include uranium, copper, potash, gold, and any other materials deemed essential by the Chair of the National Energy Dominance Council.
I speculate many of these companies could possibly even be protected further with grants or further federal orders.
These rare elements are key to defense systems, renewable energy technologies, and advanced electronics. This supply shock could significantly drive up prices. This could benefit the mining companies profits.
China supplies 63% of the antimony we use here in the U.S. Antimony is crucial for things like military equipment, metal alloys, electronics etc.
I've mentioned many diversified rare earth miners I like already on my X/Twitter account. Some are tickers NB UAMY EMX TMRC CRML NAK in addition to the new ones in this post.
Rare Earth Moly
Another key element China has made export controls on is molybdenum. In February of this year China put a control on molybdenum and other metals like tungsten, tellurium, bismuth, and indium. Exporters now need approval from China's Ministry of Commerce and General Administration of Customs, creating bottlenecks in processing shipments.
China supplies roughly half of the molybdenum or moly the U.S. uses.
Moly is extremely crucial in metal steel making, as it strengthens steel and maintains it in many other ways, like helping steel strength and stability at elevated temperatures.
The largest suppliers of steel to the U.S. are Canada, Brazil, and Mexico, which collectively accounted for about 49% of U.S. steel imports. If trade tensions further escalate perhaps the U.S. will need to make more steel domestically. Regardless, moly is always needed.
The Northern Dynasty's (NAK) Alaska Pebble deposit contains an estimated 5.6 billion pounds of molybdenum, making it one of the largest undeveloped moly resources in the world. It has yet to be approved and is not certain to but these recent trade events may further increase the chances in my view.
Pebble also has one of the worlds largest undeveloped copper resource in the whole world. There are 80.6 billion pounds of copper in total, according to some estimates. Conservative measured and indicated estimates are 57 billion pounds of copper with which is still a gigantic number.
Perpetua Resources Corp ticker (PPTA) just got approval in January to go ahead with the moly Stibnite project.
Stibnite’s 148-million-pound antimony reserve is the only identified domestic source in the US and could supply 35% of the country’s antimony demand in its first six years.
Other notable companies include Miner MP Materials (MP) owns the Mountain Pass site, which is the only large rare earth mining site of scale in the Western Hemisphere. Another rare earth miner I added to the basket is Critical Metals CRML. They have an interest in the Tanbreez Rare Earth Project in Greenland. It's one of the largest rare earth deposits globally, with an estimated 4.7 billion metric tons of host rock. "They plan to invest $10 million in further exploration and drilling by the end of this year. Once this investment is completed, the company can increase its equity stake from 42% to 92.5% by issuing additional shares worth $116 million (according to Benzinga)." There are plenty of other publicly traded miners who mine moly, but they also mine other metals with economic slowdown sensitivity like copper. These stocks have extremely high beta and aren't going to generate alpha in a market sell-off, however, when volatility is lower they can be attractive.
One such company is Freeport-McMoran (FCX) is a big mining company and one of the largest producers of moly globally.
I have picked mine based on recent months technical strength. There are also a slew of junior miners that trade on the Toronto exchange but I'm focusing on ADRs here.
Iluka Resources ticker ILKAY, is constructing Australia’s first fully integrated rare earth refinery. It appears to produce only the dysprosium and terbium on the new China list.
The stock trades on very, very thin volume so one would need to be catious of this. It's in a long downtrend, and to me, needs to get better technicals and relative strength before I'd personally consider it.
My final thoughts are there are intermediate investing opportunities in these companies as catalyst trades with small position sizes. I don't like individual mining companies as long-term investments (1-2+ years) from watching many over the years.
Some cycles certain companies stocks perform well and some cycles they don't. In the case of gold and silver it's often more advantageous to hold vehicles like ETFs,futures or even the physical itself. Full Disclosure:I hold shares of NB UAMY NAK ( stock and calls and put hedges) I plan on purchasing USAR stock and MP soon.
February 10, 2025
FiscalNote (NOTE) AI SaaS Analytics
FiscalNote ticker symbol NOTE serves a global, diverse customer base that includes businesses (including over half of the Fortune 100), government agencies, law firms, professional services organizations, trade groups and non-profits. They serve all three branches of government including the White House and Dept. of Defense.
The company was founded in 2013 by Tim Hwang and his childhood friends Gerald Yao and Jonathan Chen. They secured initial investment from notable investors including Mark Cuban and Jerry Yang.
They are the market-leading AI platform for the regulatory, legislative policy and geopolitical intelligence sectors.
To put their software in simple terms FiscalNote is like a super-smart news alert system for laws and rules that: Watches government websites and documents 24/7. It summarizes complicated legal documents into simple language and alerts you when important changes happen.
Imagine you own a business and need to know about new laws that might affect you: FiscalNote software gives quick answers instead of reading thousands of pages of government documents. Saves money and time instead of hiring expensive lawyers to explain everything. FiscalNote's software sends you a simple alert about new rules and explains how they affect your business.
In the most recent conference call management calls the software "essentially the Bloomberg terminal for regulatory, legislative and strategic risk, drawing upon a deep reservoir of technical expertise, proprietary data and analytical tools." The Bloomberg terminal is the top tier terminal used by finance professionals.
One of the positives I see about the company is that it still has founders in leading positions. Tim Hwang is a co-founder and is the current Executive Chairman. Gerald Yao is another co-founder and is Chief Strategy Officer. Tim Hwang was the CEO since the start and just a month ago is replaced by Josh Resnik at CEO.
Financials
I looked over the yearly financial report for the 2023 year. They generated total revenues of $132.6 million and $113.8 million for the years ended December 31, 2023 and 2022, respectively. So revenue grew 16% which is good growth.
They get recurring revenues through the subscription-based model, which accounts for approximately 90% of total revenues.
In 2023 gross profit margin was 82% vs 80% in 2022. These are really good gross margins and they should be able to get a net profit with these kind of margins. I'm a little surprised this net profit isn't happening now, however I see a rising trend in earnings per share the last four quarters. If this trend continues ceteris paribus they should have profitability in a year or less.
I did see in the quarter ending in March in '24 they put up a cool $.39 a share in net income or $50.5 million in net income. This was good to see because it shows that they are capable of the feat.
In the last quarter revenue was down -13% qoq. A positive was the quarter represented a $2.7 million improvement in adjusted EBITDA year over year and marked the fifth straight quarter of adjusted EBITDA profitability for FiscalNote. I really want to see more revenue come in this year though.
On the Q3 '24 earnings call they forecasted $9 million in adjusted EBITDA marking the first full calendar year of adjusted EBITDA profitability.
Valuation
I see this stock as a potential growth stock. The way I like to look at big picture valuation on growth stocks is the price to sales ratio P/S. It shows how much you are paying for the sales. Right now it's a low valuation at just 1.4 X trailing twelve month sales.
I've been looking at a lot of cheap companies lately and none of them were even less than 1.5 X sales. The big sales growth isn't here right now and the market is pricing this in. I'm bullish on the industry growth so I see a good discount here just from a sales standpoint. I'm optimistic they can grow the top-line 10%.
Industry growth
The global ai-regulatory tech industry according to market.us is expected to be worth around $29.6 Billion by 2033, from $1.3 Billion in 2023, growing at a CAGR of 36.7% during the forecast period from 2024 to 2033. That is s very good CAGR.
Institutional holders
21% of NOTE's shares are held by Maso Capital Partners. They are a Hong Kong-based hedge fund established in 2012 by Manoj Jain and Sohit Khurana, both former managing directors at Och-Ziff's Asia fund. This holding percentage is 7 times more than the next largest holders being Morgan Stanley, Vanguard and Blackrock.
Maso has about 36 positions and their top holding is NOTE which is the largest position at 35%. Other top holdings are SOHU, YY, VNET Group and i-Shares Russell 2000.
Technical Analysis
Since the IPO, the stock has never gotten enough sustained buying to put in a major technical bottom and get lasting momentum. It's threatening this here but has to see $1.61 a share hold first.
Final Thoughts
For a company as small as this they have a strong business being subscription based and with a healthy diversity of clients. The big play here is as more companies start using AI they are poised to benefit and grow fast. The current valuation makes sense if this happens.
Also, having such big gross margin makes them likely to get over the net income hump. This will likely be a positive catalyst that boosts the stock.
Disclosure: I am long stock
October 16, 2024
Bullfrog AI (BFRG) AI Drug Discover
First off, I’d like to thank my recent new followers for following me on Substack. I started the Substack in early 2023 and I now have 311 followers. Thank you all for your support.
If you have read my articles on pharma companies or follow my X account here ,you know I have been researching stocks involved in the AI (Artificial Intelligence) theme.
I believe we are still early in the theme. Big techs continued and accelerating CapEx into infrastructure supports this as well as Oracle's ORCL two most recent quarters. Companies from agriculture to Walmart are now using AI to drive results.
I’ve been an early adopter of LLMs (Large Language Models) for research and as a search engine. I’ve almost entirely replaced my Google search use by about 80-90%. I have been very open-minded to the positive future uses of these neural nets.
If you are skeptical of AI or already have a strong negative opinion on it, that’s fine. You can rest assured, for the sake of the company analysis in this article, that machine learning and AI have already been around for over a decade in computational biology and the pharmacutical industry and it has only been positive. There are plenty of articles written explaining the uses of AI and machine learning if you are curious about the uses in the pharma industry. One such article is Revolutionizing clinical trials: the role of AI in accelerating medical breakthroughs
I just watched a recent interview with Nvidia (NVDA) CEO Jensen Huang. He mentioned the industries he sees most impacted by AI in the near future. One he mentioned was digital biology. Nvidia has already invested directly into clinical biotechnology company Recursion Pharmaceuticals (RXRX). Recursions mission statement is exactly like Bullfrog AI’s (BFRG).
Recursion was founded to harness the power of accelerating technological innovations to improve the efficiency of drug discovery and development. Bullfrog AI has the same technology focused approach to drug discovery.
I knew for sure I was onto something when one of the value stocks I covered on the Substack SomaLogic got bought out by Standard Biotools (LAB) only a few months after my write-up on it. SomaLogic is a protein biomarker discovery and clinical diagnostic company. They have the SomaScan Platform. It is a tool that helps scientists study proteins in a much faster and more detailed way. It lets researchers understand how proteins work and interact with each other.
Bullfrog AI Bullfrog AI (BFRG) calls itself “an emerging digital biopharma company. Using our proprietary AI/ML analytics platform, we aim to improve drug development and clinical trials through identification of high-value data niches and patient subgroups.”
One of the most interesting things about Bullfrog is they truly are on the cutting edge of technology. They have been working with Johns Hopkins Applied Physics Lab since atleast 2017 and also collaborating with George Washington University. Both Johns Hopkins Hospital and University are some of the most renowned institutions in the nation.
In 2017 Bullfrog AI was granted licenses to a data analysis tool from Johns Hopkins. In March of 2023 they were granted additional licenses to two machine learning tools from Johns Hopkins. Their names are Prometheus and Seagull.
They also have a relationship with the Lieber Institute for Brain Development (LIBD). The collaboration between BullFrog AI and LIBD, announced in September 2023, uses the bfLEAP™ platform to mine LIBD’s comprehensive brain data. This data includes transcriptomic, genomic, DNA methylation, cell-line, clinical, and imaging data from over 2,800 brain samples. Early results announced in January 2024 highlighted the ability to stratify brain expression data, revealing biological subtypes within psychiatric disorders.
Some recent developments came for Bullfrog AI just days ago with the prospects of Bullfrogs drug candidate BF-114. There was a publication of new research in the peer-reviewed journal Cell Reports supporting the potential of BF-114 (SPTBN1 siRNA), in treating a range of liver diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), and hepatocellular carcinoma (HCC). BF-114 is being developed for the treatment of obesity and liver diseases and this research appears to be promising.
They have acquired the rights to a series of preclinical and early clinical drug assets from universities and entered into a strategic collaboration with a world-renowned research institution to create a HSV1 viral therapeutic platform to engineer immunotherapies for colorectal cancer.
They have signed exclusive worldwide license agreements with Johns Hopkins University for a cancer drug that targets glioblastoma (brain cancer), pancreatic cancer, and other cancers. They have also signed an exclusive worldwide license with George Washington University for another cancer drug that targets hepatocellular carcinoma (liver cancer), and other liver diseases.
Business Strategy
One of their business goals is to “rescue” drugs that have failed in phase 3 clinical trials by using their technology to analyze all available data with the goal of designing a precision medicine clinical trial that will have a better chance of being successful. They see this servicable market as a $47 billion market.
The Company has a unique strategy designed to reduce risk and increase the frequency of cash flow. The first part of the strategy is to generate revenues through strategic relationships with biopharma companies. These relationships will be structured as a combination of fees and intellectual property based on the specific scope of the engagement.
In the future, the second part of our strategy involves acquiring the rights to clinical stage drugs, using our bfLEAP technology to design a precision medicine trial, conduct the trial with a partner, and sell the asset. This approach may also apply to earlier phases in the drug development process such as discovery and preclinical.
The company has two main platforms.
The bfLEAP™- an AI/ML platform for analysis of preclinical and/or clinical data. This is how the company describes bfLEAP in their annual report.
"The analytics industry and application of AI in healthcare is growing rapidly. Competition exists along the entire continuum of the drug development process from discovery to commercialization and beyond.
We believe the weakness of the industry is the quality of the data and we believe bfLEAP provides several competitive advantages, that will position the Company for success.
"First, bfLEAP is highly scalable and can process data from small to extremely large complex data sets without the need for additional code being developed. Second, it is adept at processing and analyzing incomplete data and making predictions that we do not believe other technologies are capable of doing.
Finally, bfLEAP has the ability to extract the most important features for analysis out of extremely large complex data sets using unsupervised machine learning algorithms, thereby greatly simplifying complex problems. Since data quality is a problem that exists in the healthcare industry, we see these as major differentiators." -company annual 10-K
The ability to make predictions, find relationships and patterns and anomalies in extremely large complex data sets has been demonstrated by the Applied Physics Lab in other applications and sectors. Finally, the algorithms used by bfLEAP are proprietary and protected, having been developed at Johns Hopkins University Applied Physics Lab.
We believe most of the competitors rely on open-source algorithms and we also believe that we have already demonstrated our superiority via the August 2021 publication in DeepAI.org."
siRNA -for targeting Beta2-spectrin in the treatment of human diseases developed at George Washington University and licensed by the company.
Valuation Bullfrog AI has a market capitalization of $21.2 million. NCAV (net current asset value) is $5.3 mil. The company didn’t have any revenue in the most recent quarter and revenue has been very sporatic. They generated their first revenues in late 2022 from services provided to a pharmaceutical customer. In the third quarter of 2023 they completed their first commercial service contract and recognized revenue in the amount of $65,000.
For the full year in 2022 the company used $911,000 in cash. They said they expect that to increase going forward. As of the last quarter they have $7 million in cash and a very strong current ratio of 9. There is an accumulated deficit of $11.6 million.
I looked up the company address listed in their annual report at 325 Ellington Blvd, Unit 317, Gaithersburg, MD 20878. It's at what appears to be a retail shopping building. There is a UPS store on one side of it and a ZAGG on the other and a sit-down restaurant at the end of the building. There isn't a business marking on their front. Maybe the Google image is old or they just moved. I don't know.
What explains this is they also say all of the company's employees work virtually and they own no properties. Unless I am mistaken of what I am looking at on Google Maps this is unusual to me though. I was expecting to see an office building.
Technical Analysis The technicals are holding as it is on a major support level that goes way back. This last consolidation looks like a bullish flag on that level. The stock is incredibly volatile.
Full Disclosure: I am long shares of BFRG
June 12, 2024
Jones Soda JSDA Turning Around
Companies listed on the OTC/pink sheets can often be shell corporations and companies just frankly not worth owning. The listing requirements are different than the major exchanges. Jones Soda is a real company with substantial operations. They are headquartered in Seattle, WA but sell nationwide in grocery stores. I have seen their soda products on the shelf in my local grocery store here in North Carolina.
The company has always sold bottled soda drinks. They now have a fountain soda business for restaurants and customers. The more interesting developments lately have been their move into cannabis infused drinks in 2022 and craft alcohol mixers. The cannabis is under the Mary Jones brand in California and Washington. These products include 10mg and 100mg cannabis-infused soda.
There has been a push on the national level to get closer to decriminalizing marijuana just in the past year. A new federal rule announced in May will reclassify marijuana as a less-dangerous, Schedule III drug.
The trend also has been for more states to legalize marijuana and cannabis. The Florida Supreme Court made a ballot initiative earlier this year to legalize recreational marijuana in Florida. It could be on the ballot in November.
Cannabis is legal in some form, for either recreational or medical use, in more than 40 states. The fact Jones Soda is only selling their cannabis drinks in two states and Canada leaves a lot of opportunity for growth.
They say in the annual report they are planning to expand into other states. The cannabis drinks are a highly competitive market but the outlook is sure a lot better than the soda product line which they have had for years. The U.S. is 81% of their sales and Canada 19%. As of March this year they had 27 employees,15 are employed in sales and marketing.
Valuations
The company has a market cap of $40 million as of today June 12th. Trailing twelve month sales are $17 million.
The company is trading for roughly 2.3 times sales. Sales in the most recent quarter were up 29% year over year. This is a fair price for a company like this. Small companies can really grow sales fast. I think this valuation is more undervalued considering the new markets they are now in.
Gross margin improved by a nice 8% from proactive pricing adjustments, supply chain optimization, and increased sales of Mary Jones brand revenue which generally have higher margins. The company hasn't had positive free cash flow or positive earnings for a long time if ever. I see the entry into the cannabis and craft mixer drinks as a big turning point that will bring much more positive developments than prior years.
They also made some great new hires in key roles. A new CEO David Knight is joining at the end of this month! The current CEO is retiring. Mr. Knight worked at Pepsi as a vice president of marketing Gatorade and was vice president of marketing at Quaker Oats.
In March Eric Bittner joined Jones as its new Chief Operating Officer, bringing 20 years of leadership in the beverage industry to lead the company's operations. He most recently led turnarounds at Roar Organic's and Fever Tree, where he served as the SVP of North American Manufacturing. Additionally, he has held supply chain leadership positions at Keurig Dr. Pepper, Niagara Bottling, and PepsiCo.
Mary Money was named Director of New Product Development and Commercialization at Jones. Money is a highly experienced R&D scientist, with over 30 years of experience in Food and Beverage. She has worked for PepsiCo and ConAgra Foods. These are some amazing hires for a company this size and they look very lucky to have grabbed these from Pepsico together.
Final Thoughts
Usually when I look at companies this small they are at a deep value to assets on the balance sheet. Jones, however is not a deep value but the balance sheet sports a 2.36 current ratio which is an adequate ratio. Current ratio of 2 or higher shows a high likelihood of a company in general being able to pay it's short-term bills. The Company believes its cash on hand, projected cash generated from product sales and funds received from the committed revolving credit facility are sufficient to fund the Company's operations for a period of at least 12 months. The company in my opinion is in one of the best positions it's been in as long as I've known about it.
Technically, the price action has gotten momentum and the stock is up significantly this year and after their most recent quarter. It's currently in a bullish triangle pattern. I'd like to see the stock hit $.41 a share to make sure the momentum is still going to continue before buying the next couple months.
I don't currently own any shares. I may buy JSDA shares in the future. Stocks trading for less than $1 a share can be incredibly volatile and the prices can drop significantly without news or any events. If I buy it I will use limit buy orders and not a market order.
November 21, 2023
EV Charging Stocks Short Thesis
Another major factor is Tesla has a position in the EV charging space with their own charging stations and continue to get more major car manufacturers to sign on. This I believe was a big blow to these much smaller EV charging stocks that I mentioned. I don't see how these companies will compete with Tesla chargers if Tesla decides to try and corner the market. The stock prices continue to fall monthly making equity raises less and less helpful. Evgo EVGO was able to raise some capital recently. The cash burn is significant with them and BLNK. I recently added more BLNK puts and now have put options of various strikes as far out as January 21st.
The cracks are now starting to emerge in the industry as Chargepoint's CHPT CEO and CFO both announced their resignation on the same day as revenue forecast was slashed! Here is an article. Apparently, Chargepoint is "the leader" in this space which is sure something telling.
I got this graph from another account on Twitter that highlights cash burn at Chargepoint and EVgo. The recent overall stock market rally has caused minor rallies in BLNK and EVGO stocks that I see as better prices for long dated puts. There has been a turn in the press and I'm seeing negative press on these chargers. The Wallstreet Journal had an article a week ago on how the stations are not working.
r>
Disclosure: I am long put options in CHPT BLNK EVGO and will continue to add more.
October 10, 2023
Global Equity Indices Now All Weaking
Vietnam is still one of my favorite long-term investment prospects with their superior GDP growth and forecasts. Below are the respective charts of these countries equity indices. First is the iShares MSCI Emerging Markets ETF (EEM) that is near lows on the year.
The Vietnam (VNM) pull-back was pretty forcefull off the highs in September.
UAE just had a big red day coinciding with the geopolitical events and conflict. I expect to see more short-term downside here.
Lastly, beginning to weaken Turkey (TUR). I see an opportunity for a short on this market with uptrend levels being broken and the fact it hasn't had a significant pull-back yet. Also, there is the proximity to the conflict that just started in the region that may be bringing some uncertainty to the market there.
I see a short setup or a long put options setup in Teva Pharma (TEVA) based in Israel. I noticed the IZRL ETF that is the Israel Pharma ETF took a large downside move and has downside momentum going off a big gap down.
There is also a very good short setup in (TKC) Turkcell a Turkey company that has just come off a clear bear flag and is making new lows.
August 20, 2023
Defensive Opportunities In A Continued Risk Off Quarter
Last week Bitcoin saw increased selling and volatility. This just adds to the risk off sentiment as Bitcoin, one of the best performing assets this year is joining in on the selling. Below is the breakdown of the trend support currently in the works on Bitcoin. I alerted on the recent top for Bitcoin here on the blog in early 2022.
In light of this overall market weakness I see opportunity in pharmaceuticals with ETF's like VanEck Pharmaceutical ETF (PPH) and I-Shares Pharma ETF (IHE). The ETF's have recently broken out to new 52 week highs and shown relative strength in the market. I'm particularly bullish on the sector because breakthroughs in AI machine learning should improve drug development costs and increase speed of discovery and research.
I've done extensive research on the newest AI via large LLM's(large language models) and the promise of smaller ones. Drugs and biotech are some of the industries they will transform initially. They are the perfect fit for industries where scanning large language databases is key and processing large amounts of data is needed.
The pharma ETF PPH is coming up on a key support level.
Merger Arb Opportunities
There are opportunites in merger arbitrage with Spirit Airlines (SAVE) and I-Robot (IRBT). Spirit is trying to get an all cash deal done with Jetblue for $33.50 a share. Amazon has been in the works and shareholder approved to buy I-Robot for all cash or $51 a share too.
Oil and Gas Energy
Apart from pharma I have seen relative strength in energy stocks. I have particularly been looking at oil and gas stocks as natural gas has pretty much been written off. I'm not particularly bullish on natural gas but the contrarian trade now is nat gas as harsh winter weather is likely not priced in. The best gas ETF is US 12 month Fund (UNL) at it holds long dated contracts and thus has less decay than ETF (UNG). Nobody is bullish on natural gas prices as the technicals have shown a bottom formation forming.
Some of the energy stocks I added to my watchlists were VAALCO (EGY),Helix Energy (HLX), Nextier Oilfield (NEX), KLX Energy (KLXE).
Solar Weakness Continues
Another industry that caught my attention was Solar. It caught my attention as a short opportunity as the weakness in solar continues as evidenced by the Invesco ETF (TAN). I noticed short selling technical setups in stocks like JKS and MAXN too.
I'm bullish on the prospects of breakthrough technology like quantum computing with the help of AI. The quantum computer ETF is Defiance Quantum ETF (QTUM). I also particulary like the quantum computing stock Rigetti Computing (RGTI) as they have one on the cloud.
I continue to believe the investment of our lifetimes going forward will be in artificial intelligence. The best plays on this are the actively managed Roundhill ETF (CHAT) and long established Global X AI ETF (BOTZ) and Robo Global ETF (ROBO).
One good speculative investment opportunity I saw was in the Nigeria country specific Nigeria ETF (NGE). Nigeria NGE has a trailing twelve month 16% dividend yield. 0.83% expense ratio. Politics might be a partial driver of the 28% YTD performance of Nigerian stocks.
"The Tinubu admin also formed a committee on fiscal policy and tax reforms headed by Taiwo Oyedele, signalling the possibility of critical tax reforms"... " Banking and oil gas stocks have been very strong drivers of market performance. Oil and Gas stocks have been on the rise since they took out fuel subsidy from the sector. Added with banking, they are the top two sectors.”
On specific stocks on the long side I see a buy setup in Payments Holdings (PAY) as it saw large buying volume after earnings and is consolidating in a flag now. It needs to hit 14.05 for a long trade. The company has strong revenue and earnings growth. They recently revised quarterly earnings forecasts to the upside. Next years earnings guidance has been raised to $.24 EPS vs previous $.14.
Full disclosure: I have been actively trading the PPH ETF, RGTI. I have puts on JKS, long BOTZ, CHAT. May long NGE in future.
August 5, 2023
Spok Holdings (SPOK): Healthcare IT Company With a 9% Dividend Yield
Spok (SPOK) provides healthcare communication solutions in the United States, Europe, Canada, Australia, Asia, and the Middle East. They offer subscriptions to one and two-way messaging services, voicemail, and equipment loss or maintenance protection services. They serve over 2,200 health care facilities and 83% of their revenue is re-occurring in nature. The current market cap is $271 million with the stock price at $13.60 a share.
Valuation and Metrics
The trailing twelve month PE ratio is 8. Price to sales ratio is around 2. I find this to be a compelling valuation in the current market. Free cash flow has been positive since 2019, except for 2021 which was driven by unusually large capex.
The company has been profitable since the second quarter of 2022. In 2019 to 2021 net income was negative. I didn't look at any years before 2019.
Return on equity has been trending upward the past few years. The current ROE is 13% for Q2 2023.
Strong Dividend History
From 2018 to 2021 the company payed $.50 in dividends per share. In 2022 the dividend was raised to $1.25 per share.
In the years prior to 2018 the company made a total of $467 million in dividend payments.
The current quarterly payments are $.3125 per share.
With the stock at $13.60 a share the dividend yield is 9% well above the risk free rate.
In addition to shareholder friendly dividends the company also has a history of returning value through share repurchases. In 2018 and 2019 they spent a combined $40 million on sharebuybacks.
Industry Long-term Outlook
The prospects for health IT is strong.
Gobal healthcare information system market size was valued at USD 406.4 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 13.3% from 2023 to 2030. Rise in healthcare expenditure and advancements in its IT infrastructure are some of the primary drivers boosting the market. High demand for remote patient monitoring is also significantly driving its adoption rate.source: https://www.grandviewresearch.com/industry-analysis/healthcare-information-system-market
Other sources share similar growth rates. While the company has not experienced rapidly growing sales the industry growth does provide good defensive stability. The nature of the business doesn't require large debt loads and margins are healthy and stable. This lends to the prospect of meeting future dividend payments.
Technical Analysis
The stock price has been uptrending since the summer of 2022. It formed a base and recently broke out to a new 52 week high on earnings.
It has good short-term technicals with a clean bull flag on the daily chart highlighted in red.
If you like this keep it simple analysis be sure to subscribe to my free Substack where I do analysis on deep value stocks trading below net tangible and net current asset value.
Full disclosure: I have no position at the time of writing. I many take a long position in the future.
July 30, 2023
More Fast Growing Technology Companies
They have been free cash flow positive for the last four years. In 2022 free cash flow came in at a robust $103 million. 2021 had $142 mil in free cash flow, 2020 saw $64 mil.
Yalla is trading at 12 times earnings with forward growth forecasted significantly higher.
The price action is resembling the overall Chinese stock market. It just broke over a resistance level.
The technicals combined with valuation, fundamentals and recent strength in China make this a good long watch.
Nerdy, Inc. (NRDY) an $811 million company in the online education industry that utilizes AI. The companies CEO is the founder. Revenue is forecasted to grow 29%. Earnings are estimated to turn to profitablity next year.
On the balance sheet current ratio is 3. The largest mutual fund holder is Franklin Strategic Series-Franklin Small Cap Growth Fund. Goldman Sachs, Vanguard Group and Blackrock all hold over 2% of the stock each.
June 13, 2023
Undervalued Tech Stocks
The Nasdaq 100 is up 30% so far this year. It's not easy to find large-cap growing tech companies that haven't already seen significant stock accumulation.
I have been scanning the sector regularly to find attractive longer term opportunities. I remember the early 2000's very well and how accelerating revenue growth in E-commerce propelled so many stocks higher and higher.
The demand for computer power to fuel the growth of AI and large language models is here. Whether you believe it is all hype or the next paradigm of computers like me as personal computers were in the 80s and internet was in the 90s AI is getting investment.
Everyone complains that Nvidia(NVDA) is too expensive at 30 times sales. Here is some historical context on what large companies can do in a bull market.
In the 2003-2007 market Baidu (BIDU) had a price to sales ratio of 30 in spring 2010 and share price of $60. It still ran to $145 at its peak in 12' with a P/S of 44! that's a 100% return after it was at 30 times earnings. I'm not saying Nvidia will grow like that but another 25% return doesn't seem impossible.
In 2015 Alibaba BABA had a price to sales of 16 and the stock still went from $80 to $200 in 2018.
I've been looking at a lot of robotics companies, semi's, silicon miners and IT infrastructer stocks large and small. I've been tweeting about many such stocks for a couple months on Twitter. One such stock, STRC I made a substack article on. Subscribe to my Substack here to catch all my newest deep value net-net ideas.
One recent dive I did was Nauticus Robotics (KITT). It is in the ocean sensory robotics business.
-4.8 Current ratio
-+230% to +440% forward revenue growth,
-36% rev growth this current year
-EPS loss narrowing 6 quarters straight
-no dilution
-risk, only 2 customers
Another interesting thing I stumbled on was that Boston Dynamics a world leader in robotics is owned by Hyundai Motor (HYMTF). They bought the company in 2020 for $1 billion. I'm sure the current market value is much higher now in this AI frenzy.
ARB IOT Group ticker symbol (ARBB) an Asia based smart home technology company IPO'd in April of this year. There appears to be no analysts on it so it was hard to find guidance. I did see some very good growth.
There was 2,200% revenue growth in a six month period in 2022. Quarterly earnings growth was 158% per Finviz.com. The balance sheet has a 3.9 current ratio. I need to do some more research but it appears it may be below net current asset value too. The float is only 1.2 million.
Another lower float one I found was IBEX (IBEX). Earnings guidance has been steadily raised over the past few months. Earnings are expected to grow 11% next year. The forward PE ratio is 9.6.
Some of my favorite datacenter stocks are
Bel Fuse (BELFB), MongoDB (MDB), Vertiv Holdings (VRT) and a cloud company I like is Zscaler (ZS).
I currently own Nvidia through ETFs and am long KITT and STRC. I may buy or sell any of these stocks in the future. Here is an AI generated image of a modern datacenter.